GlassScriptPhysician profile
Daniel A Cawl
NPI 1760570436
$2,654.24
in general payments reported to CMS, 2019-2025
31 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $660 · 2023: $678 · 2024: $357 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.18 | 2021-2024 | |
| Novo Nordisk INC | $385.52 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $304.30 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $215.23 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.49 | 2021-2023 | Jardiance |
| Corcept Therapeutics | $118.52 | 2023-2024 | Korlym |
| Glaxosmithkline, LLC. | $116.06 | 2021-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $94.08 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.88 | 2021 | |
| Sumitomo Pharma America, INC. | $55.43 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $54.63 | 2021-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $50.20 | 2021-2022 | |
| Exact Sciences Corporation | $48.61 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $46.66 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.49 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $37.54 | 2022 | |
| Abbott Laboratories | $34.09 | 2022 | |
| Amgen INC. | $29.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.37 | 2024 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $20.30 | 2023 | Austedo Xr |
| Paratek Pharmaceuticals, INC. | $20.12 | 2023 | Nuzyra |
| Daiichi Sankyo INC. | $19.90 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.57 | 2022 | |
| Axsome Therapeutics, INC. | $18.07 | 2025 | Auvelity |
| Dexcom, INC. | $15.31 | 2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $14.57 | 2023 | Tirosint, Licart |
| Halozyme INC | $14.16 | 2023 | |
| Mannkind Corporation | $13.75 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.64 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $12.12 | 2021 | |
| Genentech USA, INC. | $5.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cawl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.